Search results
Results from the WOW.Com Content Network
Myelography is a type of radiographic examination that uses a contrast medium (e.g. iodised oil [1]) to detect pathology of the spinal cord, including the location of a spinal cord injury, cysts, and tumors.
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.
The myelogram is performed on an outpatient basis, So the patient should be properly instructed regarding limitations following the procedure such as driving. Instructions regarding postprocedural care, including warning signs of adverse reactions and the possibility of persistent headaches, should be given to the patient by a trained professional.
Tumor markers can be molecules that are produced in higher amounts by cancer cells than normal cells, but can also be produced by other cells from a reaction with the cancer. [ 2 ] The markers can't be used to give patients a diagnosis but can be compared with the result of other tests like biopsy or imaging.
For example, cancer of the thyroid gland may cause symptoms due to compressions of certain structures of the head and neck; pressure on the laryngeal nerves may cause voice changes, narrowing of the windpipe may cause stridor, pressure on the gullet may cause dysphagia and so on.
This section does not cite any sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed.
EBV-positive disease is more common in the plasmacytoma rather than multiple myeloma form of plasma cell cancer. [46] Tissues involved in EBV+ disease typically show foci of EBV+ cells with the appearance of rapidly proliferating immature or poorly differentiated plasma cells. [46] The cells express products of EBV genes such as EBER1 and EBER2 ...
At least one case of FIP1L1-PDGFRA fusion gene-induced eosinophilic leukemia presenting with myeloid sarcoma and eosinophilia has been reported. This form of myeloid sarcoma is distinguished by its highly successful treatment with imatinib (the recommended treatment for FIP1L1-PDGRGA fusion gene-induced eosinophilic leukemia) rather than more aggressive and toxic therapy.